Evidence map›Paper›PMID 31769659›Full record

ArticleAnalytical chemistry2020

Direct Determination of Antibody Chain Pairing by Top-down and Middle-down Mass Spectrometry Using Electron Capture Dissociation and Ultraviolet Photodissociation.

Jared B Shaw, Weijing Liu, Yury V Vasil Ev, Carter C Bracken, Neha Malhan, Adrian Guthals, Joseph S Beckman, Valery G Voinov

Open access · greenAbstract read
In one paragraph

Article in Analytical chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Top-Down and Middle-Down Mass Spectrometry of Antibodies.Molecular & cellular proteomics : MCP · 2025
    Review
  8. Review
  9. Revealing the Fates of Proteins in the Gas Phase.International journal of mass spectrometry · 2024
    Article
  10. Article
  11. To 200,000ACS central science · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Chemical science · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jared B ShawEnvironmental Molecular Sciences Laboratory , Pacific Northwest National Laboratory , 3335 Innovation Boulevard , Richland , Washington 99354 , United States.ORCID 0000-0002-1130-1728
Weijing LiuEnvironmental Molecular Sciences Laboratory , Pacific Northwest National Laboratory , 3335 Innovation Boulevard , Richland , Washington 99354 , United States.
Yury V Vasil Eve-MSion Inc. , 2121 NE Jack London Drive , Corvallis , Oregon 97330 , United States.
Carter C BrackenEnvironmental Molecular Sciences Laboratory , Pacific Northwest National Laboratory , 3335 Innovation Boulevard , Richland , Washington 99354 , United States.
Neha MalhanEnvironmental Molecular Sciences Laboratory , Pacific Northwest National Laboratory , 3335 Innovation Boulevard , Richland , Washington 99354 , United States.
Adrian GuthalsMapp Biopharmaceutical Inc. , 6160 Lusk Boulevard #105 , San Diego , California 92121 , United States.
Joseph S Beckmane-MSion Inc. , 2121 NE Jack London Drive , Corvallis , Oregon 97330 , United States.
Valery G Voinove-MSion Inc. , 2121 NE Jack London Drive , Corvallis , Oregon 97330 , United States.
Pacific Northwest National Laboratory · USOregon State University · USMapp Biopharmaceutical (United States) · US

Funding

Practical Mass Spectrometry Upgrade for Identifying Fragile Protein Modifications by ECDR44GM122131 · NIGMS · E-MSION, INC. · PI VOINOV, VALERY G. · 2017 to 2018
$1.8M
Practical Mass Spectrometry Upgrade for Identifying Fragile Protein Modifications by ECDR43GM122131 · NIGMS · E-MSION, INC. · PI VOINOV, VALERY G. · 2017 to 2017
$225k
NIGMS NIH HHS R43 GM122131NIGMS NIH HHS R44 GM122131
6 · The paper itself

Abstract

One challenge associated with the discovery and development of monoclonal antibody (mAb) therapeutics is the determination of heavy chain and light chain pairing. Advances in MS instrumentation and MS/MS methods have greatly enhanced capabilities for the analysis of large intact proteins yielding much more detailed and accurate proteoform characterization. Consequently, direct interrogation of intact antibodies or F(ab')2 and Fab fragments has the potential to significantly streamline therapeutic mAb discovery processes. Here, we demonstrate for the first time the ability to efficiently cleave disulfide bonds linking heavy and light chains of mAbs using electron capture dissociation (ECD) and 157 nm ultraviolet photodissociation (UVPD). The combination of intact mAb, Fab, or F(ab')2 mass, intact LC and Fd masses, and CDR3 sequence coverage enabled determination of heavy chain and light chain pairing from a single experiment and experimental condition. These results demonstrate the potential of top-down and middle-down proteomics to significantly streamline therapeutic antibody discovery.

Indexed as

Amino Acid SequenceAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalImmunoglobulin Fab FragmentsImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsMass SpectrometryPhotolysisTrastuzumabUltraviolet RaysAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalImmunoglobulin Fab FragmentsImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsTrastuzumab

Identifiers

PMID31769659
PMCPMC7819135
OpenAlexW2989662178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.